| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The primary target of BBIQ is Toll-like receptor 7 (TLR7). It acts as a potent and selective agonist, binding to TLR7 and activating TLR7-mediated signaling pathways. BBIQ has an EC50 of 59.1 nM for human TLR7. By activating TLR7, BBIQ enhances innate immune responses and has anticancer activity.
|
|---|---|
| ln Vitro |
In human PBMC (520 pg/mL at 5 µg/mL), BBIQ produces IFN-α [1].
In vitro, BBIQ has been shown to be a potent and selective TLR7 agonist with an EC50 of 59.1 nM. It activates TLR7-mediated signaling pathways, leading to the production of cytokines and interferon. The compound's activity has been confirmed in various in vitro models. |
| ln Vivo |
The parasite (Plasmodium berghei ANKA) first emerged in mice given chloroquine (CQ) alone on day 17, and on day 21 all of the mice in this group perished. Parasites did not appear in mice given BBIQ and CQ treatments until day 23. When compared to mice treated with BBIQ alone and CQ alone, mice treated with BBIQ + CQ on day 10 had reduced frequencies of T cells (CD3+, CD4+, and CD8+) and T regulatory cells (CD4+, CD25+, and FoxP3+) in the brain. In mice receiving this combination therapy, inflammatory T cell infiltration as well as the activation of T helper and T cytotoxic cells directed towards parasites were noted. On the same day, mice treated with BBIQ + CQ showed increased serum levels of IL-12 and IFN-γ, suggesting that the mice had developed a robust Th1 immune response to infection [1].
In vivo, BBIQ acts as a powerful vaccine adjuvant that enhances innate immune responses. It has anticancer activity. However, specific in vivo efficacy data from animal models are limited in the available literature. |
| Enzyme Assay |
In vitro enzyme or receptor binding assays for BBIQ are not applicable, as it is a receptor agonist rather than an enzyme inhibitor. Its activity is assessed in cell-based assays measuring TLR7 activation. The compound's ability to activate TLR7 signaling is measured using reporter gene assays.
|
| Cell Assay |
In vitro cell-based assays for BBIQ are performed using cells that express TLR7. Cells are treated with the compound, and the production of cytokines and interferon is measured by ELISA. The activation of TLR7-mediated signaling pathways is assessed.
|
| Animal Protocol |
In vivo animal experiments for BBIQ are conducted using mouse models. The compound is administered as a vaccine adjuvant, and its effects on immune responses are assessed. The compound's anticancer activity is evaluated in tumor models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of BBIQ indicate that it has a molecular weight of 330.43 and a molecular formula of C21H22N4. The CAS number is 1229024-57-0. The compound is a solid with a purity of ≥98%. Powder is stable when stored at -20°C for 3 years.
|
| Toxicity/Toxicokinetics |
Toxicology (toxicology) data for BBIQ are characteristic of a research compound. As a TLR7 agonist, its safety profile is an important consideration. The compound is generally well-tolerated at effective doses in preclinical models. However, its long-term safety profile requires further evaluation.
|
| References | |
| Additional Infomation |
Other information: BBIQ is an imidazoquinoline-based TLR7 agonist. It is a powerful vaccine adjuvant that enhances innate immune responses. The compound has anticancer activity. Its CAS number is 1229024-57-0.
|
| Molecular Formula |
C21H22N4
|
|---|---|
| Molecular Weight |
330.426184177399
|
| Exact Mass |
330.184
|
| CAS # |
1229024-57-0
|
| PubChem CID |
46830489
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
4.7
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
25
|
| Complexity |
422
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1(CC2C=CC=CC=2)C(CCCC)=NC2C(N)=NC3C=CC=CC=3C1=2
|
| InChi Key |
CQBDMXYZNLJUFT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H22N4/c1-2-3-13-18-24-19-20(25(18)14-15-9-5-4-6-10-15)16-11-7-8-12-17(16)23-21(19)22/h4-12H,2-3,13-14H2,1H3,(H2,22,23)
|
| Chemical Name |
1-benzyl-2-butylimidazo[4,5-c]quinolin-4-amine
|
| Synonyms |
TLR7 Agonist 31 TLR7Agonist31 TLR7-Agonist-31
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~16.67 mg/mL (~50.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0264 mL | 15.1318 mL | 30.2636 mL | |
| 5 mM | 0.6053 mL | 3.0264 mL | 6.0527 mL | |
| 10 mM | 0.3026 mL | 1.5132 mL | 3.0264 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
